


CLAIMS

1. An oxygen infusion for increasing an oxygen concentration in tumor tissues in living bodies, said oxygen infusion comprising a dispersion of an albumin clathrate compound including porphyrin metal complex, dispersed in a physiologically permissible aqueous media.
2. The oxygen infusion according to claim 1, wherein said porphyrin metal complex is a porphyrin metal complex represented by the general formula (I):

10 [Chem. 7]

General formula (I)




[wherein R1 is a chain or alicyclic hydrocarbon group that may have one or more substituents,

R2 is a basic axial ligand expressed by the formula (A):

[chem. 8]


Formula (A)



(where R3 is alkylene, R4 is a group that does not inhibit coordination of said basic axial ligand to a central transition metal ion M), or a basic axial ligand
 5 represented by the formula (B):

[Chem. 9]

Formula (B)




(where R5 is alkylene, R6 is alkyl); and

M is a transition metal ion of the 4th or 5th period of the periodic table of elements], and/or a porphyrin
 10 metal complex represented by the general formula [II]:

[Chem. 10]

General formula (II)




[wherein R_7 is a chain or alicyclic hydrocarbon group that may have one or more substituents,

R_8 is alkyloxy, alkylamino, amino or an amino acid derivative residue,

5 R_9 is an basic axial ligand represented by the formula [C]:

[Chem. 11]

Formula (C)




(where R_{10} is alkylene, R_{11} is a group that does not inhibit coordination of said basic axial ligand to a central transition metal ion M), or an basic axial ligand

10 represented by the formula (D):

[Chem. 12]

Formula (D)



(where R₁₂ is alkyl), and

M is a transition metal ion of the 4th or 5th period of the periodic table of elements].

3. The oxygen infusion according to claim 2, wherein
 5 said porphyrin metal complex is a porphyrin metal complex of the general formula (I), in which R₁ is C₁-C₁₉ chain hydrocarbon group having dimethyl groups at the first position or C₃-C₁₉ alicyclic hydrocarbon having a substituent at the first position, R₃ is C₁-C₁₀ alkylene,
 10 R₄ is hydrogen, methyl, ethyl or propyl, R₅ is C₁-C₁₀ alkylene, R₆ is C₁-C₁₈ alkyl, M is Fe or Co.

4. The oxygen infusion according to claim 2, wherein
 said porphyrin metal complex is a porphyrin metal complex of the general formula (II), in which R₇ is hydrogen, vinyl,
 15 ethyl or methoxy; R₈ is C₁-C₁₈ alkyloxy, C₁-C₁₈ alkylamino, amino acid or a derivative residue thereof; R₁₀ is C₁-C₁₀ alkylene; R₁₁ is hydrogen, methyl, ethyl or propyl; R₁₂ is C₁-C₁₈ alkyl; and M is Fe or Co.